• Antibodies to HHV-6 during acute COVID-19 may help predict development of Long COVID

    Autoantibodies directed against neural targets have most predictive power.

  • iciHHV-6B linked to systemic lupus erythematosus (SLE) in Japanese and European populations

    iciHHV-6B, when integrated into chromosome 22q, was strongly associated with SLE and with SLE severity.

  • HHV-6 linked to miscarriage through Mendelian randomization studies

    The findings are consistent with previous studies directly linking HHV-6 endometrial infection to miscarriage.

  • Finnish investigators find unexpected evidence of HHV-6B integration into mitochondrial DNA

    Could HHV-6B infection exacerbate mitochondrial disease?

Newsletter | About Us | Contact Us | Donate | Repository

HHV-6 Foundation | HHV-6 Disease Information for Patients, Clinicians, and Researchers | Apply for a Grant Navigation
  • Home
  • About
    • Scientific Advisory Board
    • Staff
    • Contact Us
    • Donate
  • Patients
    • What Is HHV-6?
    • HHV-6A/B Testing
  • Research
    • Grants
    • Repository
      • Cart
      • Checkout
    • HHV-6A/B Testing
    • List of Genes & Proteins
    • Lab Protocols
    • Pictorial Atlas of HHV-6
    • HHV-6 Antivirals
    • Researcher FAQ
    • Newsletter
  • Home
  • About
    • Scientific Advisory Board
    • Staff
    • Contact Us
    • Donate
  • Patients
    • What Is HHV-6?
    • HHV-6A/B Testing
  • Research
    • Grants
    • Repository
      • Cart
      • Checkout
    • HHV-6A/B Testing
    • List of Genes & Proteins
    • Lab Protocols
    • Pictorial Atlas of HHV-6
    • HHV-6 Antivirals
    • Researcher FAQ
    • Newsletter

Latest Cancer Articles

View Post

Hodgkin’s lymphoma has 3 subtypes, one linked to infection with EBV and HHV-6

In All, Cancer by Kristin LoomisFebruary 5, 2025

Outcomes worse for the subtype linked to EBV and HHV-6.

View Post

Although 28% of children undergoing chemotherapy develop herpesvirus viremia, there is minimal clinical impact

In All, Cancer, Fever, Lymphadenopathy by Kristin LoomisSeptember 16, 2024

HHV-6, CMV and HSV1/2 were the most likely to reactivate, but herpesvirus reactivation was just as likely prior to chemotherapy.

View Post

How frequent are HHV-6-related complications with CAR-T cell therapy?

In All, Cancer, Transplant Complications by Kristin LoomisSeptember 3, 2024

A combination of studies find that both reactivation and disease are infrequent after CAR-T therapy.

View Post

HHV-6B DNA associated with worse clinical outcomes in high grade serous epithelial ovarian cancer

In All, Cancer, Endocrine Conditions by Kristin LoomisJune 25, 2024

Multiplex assay for 113 viruses in tumor tissue finds six viruses, including HHV-6B, linked to reduced overall survival.

View Post

HHV-6A infection of thyroid cancer cells induces various growth-promoting changes

In All, Cancer, Endocrine Conditions by Kristin LoomisApril 18, 2024

Oncogene activation, pro-inflammatory cytokines, genomic instability, expression of oncogenic miRNAs are induced by infection.

View Post

HHV-6 detectable in some urine samples, but not linked to disease

In All, Cancer by Kristin LoomisDecember 31, 2023

In contrast, human papillomavirus found more often in urine of bladder cancer patients than in urine of patients with non-cancerous urinary tract conditions.

View Post

Part 1: Latent HHV-6 is reactivated in patients receiving CAR-T cell therapy

In All, Cancer, Immunity & Immunotherapy, Transplant Complications by Kristin LoomisApril 18, 2024

Investigators urge careful monitoring for HHV-6 and ciHHV-6.

View Post

Part 2: CAR-T cell therapy and its complications

In All, Cancer, Immunity & Immunotherapy, Transplant Complications by Kristin LoomisNovember 26, 2023

Could some complications of CAR-T cell therapy be secondary to HHV-6 infection?

View Post

Part 3. HHV-6 Encephalitis in CAR-T Cell therapy

In All, Cancer, Immunity & Immunotherapy, Transplant Complications by Kristin LoomisNovember 26, 2023

Clearly documented cases of HHV-6 encephalitis have been reported, but some are missed because they were classified as ICAN or because HHV-6 testing was not performed in patients with mental status changes.

View Post

Part 4. Might HHV-6 contribute to some cases of cytokine release syndrome, pneumonia, and cytopenias in CAR-T Cell therapy?

In All, Cancer, Immunity & Immunotherapy, Transplant Complications by Kristin LoomisNovember 26, 2023

While unlikely to trigger the cytokine storm, HHV-6 infection may perpetuate it, and contribute directly to cytopenias and pneumonia.

View Post

Differentially expressed HHV-6A/B and HHV-7 genes may have prognostic value in gliomas

In All, Cancer, Genes by Kristin LoomisFebruary 20, 2023

Unclear if viral gene expression signature confers prognostic information that is independent of host cell gene expression signatures.

View Post

HHV-6 encephalitis following CAR-T cell therapy

In All, Cancer, CNS Disease, Encephalitis & Encephalopathy, Transplant Complications, Treatments - Adoptive T cell by Kristin LoomisDecember 5, 2022

A growing number of case reports reveal reactivation similar to that seen after hematopoietic stem cell therapy. Could CAR-T cells be a source of lytic HHV-6?

View Post

HHV-6A promotes inflammation in astrocytoma cells by dysregulating autophagy

In All, Alzheimer's Disease, Cancer, CNS Disease, Latest Scientific News, Multiple Sclerosis by Kristin LoomisOctober 21, 2022

Infection increases ROS, induces ER stress and activates STAT3, NF-κB and mTOR pathways.

View Post

Does inherited chromosomal integration of HHV-6 at 9q increase the risk of malignancy?

In All, Cancer, Genes, Latest Scientific News by Kristin LoomisSeptember 26, 2022

A large study of iciHHV-6 integration sites found integration at 9q more common in hematologic malignancies—but the study lacked power to draw firm conclusions.

View Post

Adult patients with lower levels of anti-HHV-6 IgG are significantly more likely to experience HHV-6 reactivation following cord blood transplant

In All, Cancer, Hematological Disorders, Transplant Complications by Kristin LoomisMay 20, 2022

Patients with low levels of HHV-6 antibodies might benefit from treatment from IVIG or novel neutralizing antibodies before cord blood transplantation

  • Page 1 of 3
  • 1
  • 2
  • 3
  • →

Clinical News

  • Alzheimer’s Disease
  • Animal Models
  • Autoimmune Disease
  • Cancer
  • iciHHV-6
  • CNS Disease
  • COVID-19 / HHV-6 Reactivation
  • Drug Hypersensitivity
  • Encephalitis & Encephalopathy
  • Endocrine Conditions
  • Epilepsy and Seizures
  • Gastrointestinal
  • Genes
  • Heart Disease
  • Hematological Disorders
  • HIV/AIDS Progression
  • Immunity & Immunotherapy
  • Infertility & Miscarriage
  • Kidney Disease
  • Liver Disease
  • Lung Disease
  • Lymphadenopathy & Fever
  • ME/CFS
  • Multiple Sclerosis
  • Rash & Roseola
  • Transplant Complications
  • Treatments – Adoptive T cell
  • Treatments – Alternative
  • Treatments – Antiviral
  • Treatments – Immune Stimulant

About HHV-6

  • What Is HHV-6?
  • What is Inherited Chromosomally Integrated HHV-6
  • HHV-6 Repository of Reagents
  • HHV-6A/B Testing
  • HHV-6 Treatment

SUBSCRIBE TO OUR NEWSLETTER

ABOUT THE HHV-6 FOUNDATION

The HHV-6 Foundation in a non-profit entity founded to encourage scientific exchange between investigators and to provide pilot grants for promising scientific and clinical research on the under- appreciated viruses HHV-6A and HHV-6B.

The Foundation sponsors international conferences and supports scientists and clinicians seeking to clarify the role of the two HHV-6 viruses in disease. Since HHV-6A and HHV-6B can smolder in the brain and other organs without circulating in the peripheral blood or plasma, identifying chronic infection is a challenge.

Read More

HHV-6 Foundation | 1482 East Valley Road, Suite 619 | Santa Barbara, CA, 93108 | Toll Free: (888) 530-6726


Copyright ©2004-2022 HHV-6 FOUNDATION


WEB DESIGN AND DEVELOPMENT BY INSTYLE TECHNOLOGIES
  • Home
  • About
  • Conditions
  • Clinicians
  • Testing
  • Research
  • Repository
  • Patients
  • Treatment
  • News & Blog
  • Donate
  • Contact Us
  • Cart
  • Checkout
  • Privacy Policy
  • Terms of Use